FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• The biological function of FOXK2, despite its clinical association with developmental defects, is largely unknown.
• Understanding FOXK2's role is crucial for developing novel therapeutic strategies against cancer.

Purpose of the Study:

• To elucidate the biological function of FOXK2 in breast cancer.
• To investigate the regulatory mechanisms and prognostic significance of FOXK2 in breast cancer progression.

Main Methods:

• Co-immunoprecipitation assays to identify interacting protein complexes.
• Gene expression analysis (e.g., qRT-PCR, Western blotting) to assess target gene regulation.
• Cell proliferation, invasion, and migration assays in breast cancer cell lines.
• Correlation analysis between FOXK2 expression and clinical parameters in patient cohorts.

Main Results:

• FOXK2 interacts with corepressor complexes (NCoR/SMRT, SIN3A, NuRD, REST/CoREST) to repress genes like HIF1β and EZH2, modulating the hypoxic response.
• FOXK2 inhibits breast cancer cell proliferation, invasion, growth, and metastasis.
• FOXK2 is regulated by ERα and HIF1β/EZH2 feedback loops.
• FOXK2 expression is lost during breast cancer progression and inversely correlates with poor prognostic markers (high grade, lymph node positivity, triple-negative status).

Conclusions:

• FOXK2 acts as a tumor suppressor in breast cancer by regulating critical oncogenic pathways.
• Loss of FOXK2 expression is a significant indicator of poor prognosis in breast cancer patients.
• Targeting FOXK2 or its regulatory pathways may offer new therapeutic avenues for aggressive breast cancers.